Intravenous Immunoglobulin for Unverricht-Lundborg Disease.

• Status: Unknown status
• Trial end date: 2017-12-30
• Target enrollment: 0
• Participant gender: Male

Summary

Single patient randomized double blind trial to assess whether intravenous immunoglobulin can improve the clinical outcome of a case suffering from Unverricht-Lundborg disease.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Azienda Socio Sanitaria Territoriale di Mantova
• Treatments: Antibodies; gamma-Globulins; Immunoglobulins; Immunoglobulins, Intravenous; Rho(D) Immune Globulin

Criteria

Inclusion Criteria:

• Malattia di Unverricht-Lundborg (genetic diagnosis)

Exclusion Criteria:

• Contraindications to intravenous immunoglobulin